Showing results (161-170 of 364) with videos related to
Sort By:
Pageof 37
Journal of Drugs in Dermatology : JDD|August 9, 2023
Long-Term Safety and Efficacy of Twice-Daily Topical Clascoterone Cream 1% in Patients Greater Than or Equal to 12 Years of Age With Acne VulgarisLawrence F Eichenfield, Adelaide A Hebert, Linda Stein Gold, et al.Journal of the American Academy of Dermatology|April 21, 2004
Venous malformations in blue rubber bleb nevus syndrome: variable onset of presentationWalter K Nahm, Sharon Moise, Lawrence F Eichenfield, et al.The Journal of Clinical and Aesthetic Dermatology|February 18, 2017
Emerging Issues in Adult Female AcneJoshua A Zeichner, Hillary E Baldwin, Fran E Cook-Bolden, et al.Journal of Drugs in Dermatology : JDD|January 11, 2024
Integrated Short-Term and Long-Term Efficacy of Topical Clascoterone Cream 1% in Patients Aged 12 Years or Older With Acne VulgarisLawrence F Eichenfield, Linda Stein Gold, Jenny Han, et al.Allergy|July 17, 2023
Tralokinumab therapy for moderate-to-severe atopic dermatitis: Clinical outcomes with targeted IL-13 inhibitionEric L Simpson, Emma Guttman-Yassky, Lawrence F Eichenfield, et al.Journal of the American Academy of Dermatology|March 22, 2002
Safety and efficacy of pimecrolimus (ASM 981) cream 1% in the treatment of mild and moderate atopic dermatitis in children and adolescentsLawrence F Eichenfield, Anne W Lucky, Mark Boguniewicz, et al.Pediatric Dermatology|January 19, 2019
The microbiome in preadolescent acne: Assessment and prospective analysis of the influence of benzoyl peroxideJusleen Ahluwalia, Jenna Borok, Ellen S Haddock, et al.American Journal of Clinical Dermatology|February 18, 2021
Pooled Results of Two Randomized Phase III Trials Evaluating VP-102, a Drug-Device Combination Product Containing Cantharidin 0.7% (w/v) for the Treatment of Molluscum ContagiosumLawrence F Eichenfield, Elaine Siegfried, Pearl Kwong, et al.JAMA Dermatology|February 27, 2020
Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults With Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical TrialEmma Guttman-Yassky, Andrew Blauvelt, Lawrence F Eichenfield, et al.JAAD International|August 19, 2021
Therapeutic education in atopic dermatitis: A position paper from the International Eczema CouncilLawrence F Eichenfield, Ayan Kusari, Allison M Han, et al.Pageof 37